Protalex (PRTX) 10-Q 14 Apr 14 2014 Q3 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
	Feb. 28, 2014	Apr. 14, 2014
Document Information [Line Items]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	28-Feb-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Trading Symbol	'PRTX	'
Entity Common Stock, Shares Outstanding	'	28,767,582
Entity Registrant Name	'PROTALEX INC	'
Entity Central Index Key	'0001099215	'
Current Fiscal Year End Date	'--05-31	'
Entity Filer Category	'Smaller Reporting Company	'

CONDENSED_BALANCE_SHEETS

CONDENSED BALANCE SHEETS (USD $)	Feb. 28, 2014	31-May-13
CURRENT ASSETS:	'	'
Cash and cash equivalents	$2,716,459	$2,457,046
Prepaid expenses	67,214	42,320
Total current assets	2,783,673	2,499,366
OTHER ASSETS:	'	'
Intellectual technology property, net of accumulated amortization of $13,833 and $13,068 as of February 28, 2014 and May 31, 2013, respectively	5,702	6,467
Total other assets	5,702	6,467
Total Assets	2,789,375	2,505,833
CURRENT LIABILITIES:	'	'
Accounts payable	475,022	671,738
Accrued expenses	32,773	62,517
Current portion - long term debt, related party,	0	4,210,833
Total current liabilities	507,795	4,945,088
LONG TERM LIABILITIES:	'	'
Senior Secured Note - related party	9,219,366	6,000,000
Senior Secured Note Accrued Interest - related party	107,076	57,616
Total liabilities	9,834,237	11,002,704
STOCKHOLDERS' EQUITY (DEFICIT)	'	'
Preferred stock, par value $0.00001, 1,000,000 shares authorized; none issued and outstanding	0	0
Common stock, par value $0.00001, 100,000,000 shares authorized; 28,767,582 and 18,926,615 shares issued and outstanding, respectively	288	189
Additional paid in capital	62,743,260	53,237,993
Deficit accumulated during the development stage	-69,788,410	-61,735,053
Total stockholders' equity (deficit)	-7,044,862	-8,496,871
Total liabilities and stockholders' equity (deficit)	$2,789,375	$2,505,833

CONDENSED_BALANCE_SHEETS_Paren

CONDENSED BALANCE SHEETS (Parenthetical) (USD $)	Feb. 28, 2014	31-May-13
Intellectual technology property, accumulated amortization	$13,833	$13,068
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	28,767,582	18,926,615
Common stock, shares outstanding	28,767,582	18,926,615

CONDENSED_STATEMENTS_OF_OPERAT

CONDENSED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		9 Months Ended		173 Months Ended
	Feb. 28, 2014	Feb. 28, 2013	Feb. 28, 2014	Feb. 28, 2013	Feb. 28, 2014
Revenues	$0	$0	$0	$0	$0
Operating Expenses	'	'	'	'	'
Research and development (including depreciation and amortization)	837,253	984,547	2,455,781	2,494,681	38,831,275
Administrative (including depreciation and amortization)	4,007,672	425,848	4,987,433	983,535	24,801,869
Professional fees	135,722	113,077	396,386	326,655	5,467,988
Depreciation and amortization	255	255	765	765	183,731
Operating loss	-4,980,902	-1,523,727	-7,840,365	-3,805,636	-69,284,863
Other income (expense)	'	'	'	'	'
Interest income	1	2	3	29	2,211,850
Interest expense	-68,662	-91,283	-212,995	-594,400	-2,715,397
Net loss	($5,049,563)	($1,615,008)	($8,053,357)	($4,400,007)	($69,788,410)
Weighted average number of common shares outstanding	28,484,781	18,926,683	25,361,747	18,926,683	'
Loss per common share - basic and diluted	($0.18)	($0.09)	($0.32)	($0.23)	'

CONDENSED_STATEMENT_OF_CHANGES

CONDENSED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIENCY) (USD $)

Total

Employee

Board Members, Employees and Consultants

Private Placement

Employees and Debt Holders

Issuance During Period 1st

Issuance During Period 1st

Issuance During Period 1st

Issuance During Period 2nd

Issuance During Period 2nd

Issuance During Period 2nd

Issuance During Period 2nd

Issuance During Period 3rd

Issuance During Period 3rd

Issuance During Period 3rd

Issuance During Period 3rd

Issuance During Period 4th

Issuance During Period 4th

Issuance During Period 5th

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Additional Paid in Capital

Additional Paid in Capital

Additional Paid in Capital

Additional Paid in Capital

Additional Paid in Capital

Additional Paid in Capital

Additional Paid in Capital

Additional Paid in Capital

Additional Paid in Capital

Additional Paid in Capital

Additional Paid in Capital

Additional Paid in Capital

Additional Paid in Capital

Additional Paid in Capital

Additional Paid in Capital

Additional Paid in Capital

Additional Paid in Capital

Additional Paid in Capital

Additional Paid in Capital

Common Stock- Contra

Common Stock- Contra

Common Stock- Contra

Common Stock- Contra

Common Stock- Contra

Common Stock- Contra

Common Stock- Contra

Common Stock- Contra

Common Stock- Contra

Common Stock- Contra

Common Stock- Contra

Common Stock- Contra

Common Stock- Contra

Common Stock- Contra

Common Stock- Contra

Common Stock- Contra

Common Stock- Contra

Common Stock- Contra

Common Stock- Contra

Deficit Accumulated During The Development Stage

Deficit Accumulated During The Development Stage

Deficit Accumulated During The Development Stage

Deficit Accumulated During The Development Stage

Deficit Accumulated During The Development Stage

Deficit Accumulated During The Development Stage

Deficit Accumulated During The Development Stage

Deficit Accumulated During The Development Stage

Deficit Accumulated During The Development Stage

Deficit Accumulated During The Development Stage

Deficit Accumulated During The Development Stage

Deficit Accumulated During The Development Stage

Deficit Accumulated During The Development Stage

Deficit Accumulated During The Development Stage

Deficit Accumulated During The Development Stage

Deficit Accumulated During The Development Stage

Deficit Accumulated During The Development Stage

Deficit Accumulated During The Development Stage

Deficit Accumulated During The Development Stage

President

Employee

President

Employee

Private Placement

Legal Service

Employee

Private Placement

Terminated Employee

Employee

Interest Due

Employee

Board Members, Employees and Consultants

Private Placement

Employees and Debt Holders

Issuance During Period 1st

Issuance During Period 1st

Issuance During Period 1st

Issuance During Period 2nd

Issuance During Period 2nd

Issuance During Period 2nd

Issuance During Period 2nd

Issuance During Period 3rd

Issuance During Period 3rd

Issuance During Period 3rd

Issuance During Period 3rd

Issuance During Period 4th

Issuance During Period 4th

Issuance During Period 5th

Employee

Board Members, Employees and Consultants

Private Placement

Employees and Debt Holders

Issuance During Period 1st

Issuance During Period 1st

Issuance During Period 1st

Issuance During Period 2nd

Issuance During Period 2nd

Issuance During Period 2nd

Issuance During Period 2nd

Issuance During Period 3rd

Issuance During Period 3rd

Issuance During Period 3rd

Issuance During Period 3rd

Issuance During Period 4th

Issuance During Period 4th

Issuance During Period 5th

Employee

Board Members, Employees and Consultants

Private Placement

Employees and Debt Holders

Issuance During Period 1st

Issuance During Period 1st

Issuance During Period 1st

Issuance During Period 2nd

Issuance During Period 2nd

Issuance During Period 2nd

Issuance During Period 2nd

Issuance During Period 3rd

Issuance During Period 3rd

Issuance During Period 3rd

Issuance During Period 3rd

Issuance During Period 4th

Issuance During Period 4th

Issuance During Period 5th

Employee

Board Members, Employees and Consultants

Private Placement

Employees and Debt Holders

Issuance During Period 1st

Issuance During Period 1st

Issuance During Period 1st

Issuance During Period 2nd

Issuance During Period 2nd

Issuance During Period 2nd

Issuance During Period 2nd

Issuance During Period 3rd

Issuance During Period 3rd

Issuance During Period 3rd

Issuance During Period 3rd

Issuance During Period 4th

Issuance During Period 4th

Issuance During Period 5th

President

Employee

President

Employee

Private Placement

Legal Service

Employee

Private Placement

Terminated Employee

Employee

Interest Due

President

Employee

President

Employee

Private Placement

Legal Service

Employee

Private Placement

Terminated Employee

Employee

Interest Due

President

Employee

President

Employee

Private Placement

Legal Service

Employee

Private Placement

Terminated Employee

Employee

Interest Due

President

Employee

President

Employee

Private Placement

Legal Service

Employee

Private Placement

Terminated Employee

Employee

Interest Due

Beginning Balance at Sep. 16, 1999

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

September 17, 1999 - initial issuance of 2,000 shares for intellectual technology license at $.15 per share (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

September 17, 1999 - initial issuance of 2,000 shares for intellectual technology license at $.15 per share

300

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

300

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

September 30, 1999 - cost of public shell acquisition over net assets acquired to be accounted for as a Recapitalization (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

September 30, 1999 - cost of public shell acquisition over net assets acquired to be accounted for as a Recapitalization

-250,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-250,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

17

'

'

91,889

'

'

'

20,000

'

'

'

128,000

'

329

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

'

'

'

25,000

'

'

165,400

'

'

'

15,000

'

'

'

640,000

'

1,644

'

'

'

'

'

25,000

'

'

165,400

'

'

'

15,000

'

'

'

640,000

'

1,644

'

'

'

'

'

0

'

'

0

'

'

'

0

'

'

'

0

'

0

'

'

'

'

'

0

'

'

0

'

'

'

0

'

'

'

0

'

0

'

'

'

'

'

0

'

'

0

'

'

'

0

'

'

'

0

'

0

November 15, 1999 - reverse merger transaction with Enerdyne Corporation, net transaction amounts (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,794,493

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

November 15, 1999 - reverse merger transaction with Enerdyne Corporation, net transaction amounts

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

118,547

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-118,547

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-250,689

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-250,689

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Ending balance at May. 31, 2000

346,655

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

965,891

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-368,547

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-250,689

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Ending balance (in shares) at May. 31, 2000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,036,728

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

85,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

425,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

425,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

May 31, 2001 - Forgiveness of debt owed to stockholder (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

May 31, 2001 - Forgiveness of debt owed to stockholder

40,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

40,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-553,866

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-553,866

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Ending balance at May. 31, 2001

257,789

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,390,891

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

40,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-368,547

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-804,555

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Ending balance (in shares) at May. 31, 2001

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,121,728

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

August 13, 2001 - Contribution by stockholders

143,569

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

143,569

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

August 13, 2001 - Contribution by stockholders (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

176,320

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

1,102,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,102,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

November 26, 2001 - options issued to board member

133,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

133,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-1,280,465

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-1,280,465

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Ending balance at May. 31, 2002

355,893

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,492,891

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

316,569

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-368,547

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-2,085,020

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Ending balance (in shares) at May. 31, 2002

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,298,048

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Purchase of common stock from stockholder (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-26,191

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Purchase of common stock from stockholder

-91,667

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-91,667

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

168,400

'

'

'

8,334

'

'

'

1,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

'

'

'

1,263,000

'

'

'

82,841

'

'

'

11,250

'

'

'

'

'

'

'

'

'

'

1,263,000

'

'

'

82,841

'

'

'

11,250

'

'

'

'

'

'

'

'

'

'

0

'

'

'

0

'

'

'

0

'

'

'

'

'

'

'

'

'

'

0

'

'

'

0

'

'

'

0

'

'

'

'

'

'

'

'

'

'

0

'

'

'

0

'

'

'

0

'

'

'

'

'

Compensation related to stock options issued

'

'

287,343

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

287,343

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-1,665,090

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-1,665,090

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Ending balance at May. 31, 2003

243,570

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,758,315

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

603,912

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-368,547

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-3,750,110

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Ending balance (in shares) at May. 31, 2003

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,449,591

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Purchase of common stock from stockholder (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-2,419

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Purchase of common stock from stockholder

-8,333

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-8,333

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

September 19, 2003 - repurchase and retired 598,961 shares for $300,000 (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-598,961

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

September 19, 2003 - repurchase and retired 598,961 shares for $300,000

-300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,667

'

'

'

'

1,489,129

'

'

'

7,880

'

10,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

'

'

'

'

16,418

'

'

'

'

11,356,063

'

'

'

102,438

'

127,500

'

'

'

'

'

'

'

16,418

'

'

'

'

11,356,063

'

'

'

102,438

'

127,500

'

'

'

'

'

'

'

0

'

'

'

'

0

'

'

'

0

'

0

'

'

'

'

'

'

'

0

'

'

'

'

0

'

'

'

0

'

0

'

'

'

'

'

'

'

0

'

'

'

'

0

'

'

'

0

'

0

'

May 31, 2004 - reclassify common stock contra to common stock (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

May 31, 2004 - reclassify common stock contra to common stock

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-368,547

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

368,547

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Compensation related to stock options issued

'

'

448,096

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

448,096

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-2,989,364

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-2,989,364

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Ending balance at May. 31, 2004

8,996,388

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

14,683,854

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,052,008

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-6,739,474

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Ending balance (in shares) at May. 31, 2004

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,356,887

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

November 30, 2004 - adjust March 1, 2004 common stock issued to employee (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

November 30, 2004 - adjust March 1, 2004 common stock issued to employee

'

-20,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-20,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

February 28, 2005 - reclass par value for reincorporation into DE as of 12/1/04

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-14,702,070

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

14,702,070

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,000

'

'

'

518,757

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

'

'

'

'

'

38,250

'

'

'

4,851,193

'

'

'

'

'

'

'

'

'

'

'

'

'

'

38,250

'

'

'

5

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

4,851,188

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

0

'

'

'

'

'

'

'

Compensation related to stock options issued

'

'

308,711

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

308,711

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-5,567,729

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-5,567,729

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Ending balance at May. 31, 2005

8,606,813

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

39

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20,913,977

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-12,307,203

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Ending balance (in shares) at May. 31, 2005

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,878,644

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants exercised (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

70,320

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants exercised

786,538

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

786,537

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8,000

'

'

2,000

'

'

'

519,026

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

'

'

'

'

'

100,000

'

'

25,000

'

'

'

5,510,967

'

'

'

'

'

'

'

'

'

'

'

0

'

'

0

'

'

'

5

'

'

'

'

'

'

'

'

'

'

'

100,000

'

'

25,000

'

'

'

5,510,962

'

'

'

'

'

'

'

'

'

'

'

0

'

'

0

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

0

'

'

0

'

'

'

0

'

'

'

'

Compensation related to stock options issued

'

'

404,679

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

404,679

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-6,104,402

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-6,104,402

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Ending balance at May. 31, 2006

9,329,595

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

45

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

27,741,155

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-18,411,605

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Ending balance (in shares) at May. 31, 2006

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,477,990

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants exercised (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

26,700

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants exercised

300,374

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

300,374

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

June 1, 2006 - May 31, 2007 - stock options exercised (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,200

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

June 1, 2006 - May 31, 2007 - stock options exercised

15,200

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15,200

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share based compensation (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share based compensation

'

'

1,826,850

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,826,850

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,214,203

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

'

14,217,721

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

12

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

14,217,709

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-8,451,942

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-8,451,942

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Ending balance at May. 31, 2007

17,237,798

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

57

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

44,101,288

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-26,863,547

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Ending balance (in shares) at May. 31, 2007

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,720,093

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share based compensation (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share based compensation

'

'

1,011,025

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,011,025

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-10,490,758

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-10,490,758

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Ending balance at May. 31, 2008

7,758,065

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

57

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

45,112,313

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-37,354,305

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Ending balance (in shares) at May. 31, 2008

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,720,093

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share based compensation (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share based compensation

'

'

753,268

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

753,268

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-7,230,206

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-7,230,206

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Ending balance at May. 31, 2009

1,281,127

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

57

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

45,865,581

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-44,584,511

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Ending balance (in shares) at May. 31, 2009

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,720,093

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share based compensation (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share based compensation

'

'

'

'

335,741

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

335,741

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8,695,652

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

2,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

87

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,999,913

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Record beneficial conversion value attached to senior secured convertible debt

521,793

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

521,793

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-3,067,842

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-3,067,842

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Ending balance at May. 31, 2010

1,070,819

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

144

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

48,723,028

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-47,652,353

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Ending balance (in shares) at May. 31, 2010

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

14,415,745

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share based compensation (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share based compensation

'

'

'

'

124,722

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

124,722

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,510,870

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

1,037,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

45

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,037,455

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Record beneficial conversion value attached to senior secured convertible debt

1,616,667

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,616,667

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of additional shares - reverse split

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

68

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-3,357,882

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-3,357,882

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Ending balance at May. 31, 2011

491,826

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

189

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

51,501,872

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-51,010,235

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Ending balance (in shares) at May. 31, 2011

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

18,926,683

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share based compensation (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share based compensation

'

'

'

'

829,144

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

829,144

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-4,444,584

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-4,444,584

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Ending balance at May. 31, 2012

-3,123,614

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

189

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

52,331,016

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-55,454,819

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Ending balance (in shares) at May. 31, 2012

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

18,926,683

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share based compensation (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share based compensation

'

'

'

'

906,977

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

906,977

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-6,280,234

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-6,280,234

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Ending balance at May. 31, 2013

-8,496,871

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

189

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

53,237,993

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-61,735,053

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Ending balance (in shares) at May. 31, 2013

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

18,926,683

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share based compensation (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share based compensation

'

4,568,763

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,568,763

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued (in shares)

800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

9,369,565

'

'

471,334

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

'

'

'

2,155,000

'

'

2,781,603

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

94

'

'

5

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,154,906

'

'

2,781,598

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

0

'

'

'

'

'

'

'

'

'

'

Net loss

-8,053,357

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-8,053,357

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Ending balance at Feb. 28, 2014

($7,044,862)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$288

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$62,743,260

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

($69,788,410)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Ending balance (in shares) at Feb. 28, 2014

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

28,767,582

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

CONDENSED_STATEMENT_OF_CHANGES1

CONDENSED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIENCY) (Parenthetical) (USD $)

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

31-May-00

31-May-11

31-May-10

31-May-04

31-May-03

31-May-02

31-May-01

Feb. 28, 2014

31-May-00

31-May-03

Feb. 28, 2014

31-May-00

31-May-00

31-May-00

31-May-00

31-May-00

31-May-00

31-May-04

31-May-03

31-May-06

31-May-05

31-May-06

31-May-03

31-May-04

31-May-07

31-May-05

31-May-04

31-May-06

31-May-04

Issuance During Period 1st

Issuance During Period 1st

Issuance During Period 1st

Issuance During Period 2nd

Issuance During Period 2nd

Issuance During Period 2nd

Issuance During Period 4th

Issuance During Period 4th

Legal Service

Interest Due

President

President

Employee

Employee

Employee

Employee

Employee

Private Placement

Private Placement

Private Placement

Private Placement

Terminated Employee

Issuance During Period 3rd

Issuance During Period 5th

Issuance During Period 1st

Issuance During Period 2nd

Issuance During Period 1st

Issuance During Period 1st

Issuance During Period 2nd

Issuance During Period 3rd

Issuance During Period 4th

Issuance During Period 2nd

Issuance During Period 2nd

Issuance During Period 3rd

Issuance During Period 3rd

Common Stock issued, per share

$0.15

'

$0.23

'

'

$6.25

$5

'

'

$7.50

'

$1.80

'

$5

'

'

'

'

'

'

$12.75

'

'

$12.75

$12.50

$9.75

$8.50

$11.25

$13

Common Stock issued, issuance start date

'

'

'

'

'

'

'

'

'

'

'

'

18-Nov-99

'

1-May-00

'

'

'

15-Jan-03

'

'

'

'

'

'

'

'

'

'

Common Stock issued, issuance date

17-Sep-99

11-Feb-11

11-Nov-09

'

'

7-Nov-01

7-Dec-00

27-Aug-13

27-Oct-99

5-Jul-02

23-Jan-14

'

'

'

'

1-Jan-00

27-May-00

15-Jun-03

'

23-Aug-05

13-Jan-05

19-Oct-05

14-May-03

1-Mar-04

7-Jul-06

25-May-05

18-Sep-03

30-Dec-05

12-Dec-03

Common Stock issued, issuance end date

'

'

'

'

'

'

'

'

'

'

'

'

7-Feb-00

'

27-May-00

'

'

'

15-May-03

'

'

'

'

'

'

'

'

'

'

Common stock shares repurchased, per share

'

'

'

'

$3.50

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock shares repurchased, start date

'

'

'

'

1-Jul-02

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock shares repurchased, end date

'

'

'

'

1-May-03

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock shares repurchased, date

'

'

'

15-Jun-03

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock shares repurchased and retired, date

'

'

'

19-Sep-03

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

CONDENSED_STATEMENTS_OF_CASH_F

CONDENSED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended		173 Months Ended
	Feb. 28, 2014	Feb. 28, 2013	Feb. 28, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'	'
Net loss	($8,053,357)	($4,400,007)	($69,788,410)
Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities	'	'	'
(Gain) on disposal of equipment, net	0	0	-81,544
Depreciation and amortization	765	531,265	1,971,905
Equity based expense	4,568,763	658,488	13,162,734
(Increase)/decrease in:	'	'	'
Prepaid expenses and deposits	-24,894	-24,756	-75,204
Increase/(decrease) in:	'	'	'
Accounts payable and accrued expenses	-13,467	-250,927	1,394,740
Net cash and cash equivalents used in operating activities	-3,522,190	-3,485,937	-53,415,778
CASH FLOWS FROM INVESTING ACTIVITIES:	'	'	'
Acquisition of intellectual technology license - fee portion	0	0	-20,000
Refund of security deposits	0	0	7,990
Acquisition of equipment	0	0	-905,936
Excess of amounts paid for public shell over assets acquired to be accounted for as a recapitalization	0	0	-250,000
Proceeds from disposal of equipment	0	0	229,135
Net cash and cash equivalents used in investing activities	0	0	-938,811
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'	'
Proceeds from stock issuance, including options and warrants exercised	2,781,603	0	45,440,061
Principal payment on equipment notes payable and capital leases	0	0	-295,411
Contribution by stockholders	0	0	183,569
Principal payment on note payable to individuals	0	0	-225,717
Issuance of note payable to individuals	1,000,000	5,000,000	12,368,546
Acquisition of common stock	0	0	-400,000
Net cash and cash equivalents provided by financing activities	3,781,603	5,000,000	57,071,048
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	259,413	1,514,063	2,716,459
Cash and cash equivalents, beginning of period	2,457,046	190,395	0
Cash and cash equivalents, ending of period	2,716,459	1,704,458	2,716,459
SUPPLEMENTAL SCHEDULE OF CASH FLOW INFORMATION:	'	'	'
Interest paid	0	0	66,770
Taxes paid	0	0	100
NON-CASH FINANCING ACTIVITIES:	'	'	'
Conversion of debt for equity	$2,155,000	$0	$3,192,500

ORGANIZATION_AND_BUSINESS_ACTI

ORGANIZATION AND BUSINESS ACTIVITIES	9 Months Ended
	Feb. 28, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
ORGANIZATION AND BUSINESS ACTIVITIES	'
	NOTE 1. ORGANIZATION AND BUSINESS ACTIVITIES
	Protalex, Inc., a Delaware corporation, (“we,” “us,” “our,” the “Company” or “its”) is a development stage company focused on the development of a class of biopharmaceutical drugs for treating autoimmune and inflammatory diseases including rheumatoid arthritis (RA). Our lead product, PRTX-100, is a formulation of a proprietary, highly-purified form of staphylococcal protein A, which is an immunomodulatory protein produced by bacteria. PRTX-100 has demonstrated effectiveness in animal models of autoimmune diseases and has demonstrated activity on cultured human immune cells at very low concentrations, although the effectiveness of PRTX-100 shown in pre-clinical studies using animal models may not be predictive of the results that we would see in future human clinical trials. The safety, tolerability and PK of PTRX-100 in humans have now been characterized in four clinical studies, with a fifth clinical study nearing completion as detailed below. We are currently seeking regulatory approval to initiate clinical studies in an orphan indication and approval for an orphan drug designation. We do not anticipate generating operating revenue for the foreseeable future and do not currently have any products that are marketable.
	In August 2010, we commenced a multi-center Phase 1b clinical trial of PRTX-100 in South Africa in adult patients with active RA on methotrexate or leflunomide (the “PRTX-100-103 Study”). The PRTX-100-103 Study served to evaluate safety and potential efficacy of PRTX-100 in patients with active RA and was approved to enroll up to 40 patients in four dose-escalating cohorts. In January 2012, we completed patient dosing in the PRTX-100-103 Study with a total of 37 patients enrolled in four cohorts ranging from 0.15 micrograms/kg to 1.50 micrograms/kg of PRTX-100 or placebo, administered weekly for four weeks. Measures of safety, PK and disease activity were evaluated over 16 weeks following the first dose. The PRTX-100-103 Study results demonstrated that PRTX-100 was generally safe and well-tolerated in patients with active RA at all tested dose levels. More patients in the 0.90 micrograms/kg and 1.50 micrograms/kg cohorts showed improvement in their CDAI than did patients in the lower dose or placebo cohorts.
	In November 2012, we commenced enrollment in the United States for a new multicenter Phase 1b randomized, multiple-dose, dose-escalation study (the “PRTX-100-104 Study”) of PRTX-100 in combination with methotrexate or leflunomide in adult patients with active RA. The sequential dose-escalation phase of this study was expected to enroll up to 40 patients into five cohorts ranging from 1.50 micrograms/kg up to 18.0 micrograms/kg of PRTX-100 or placebo. At each dose, one quarter of patients would receive a placebo treatment. Similar to the PRTX-100-103 Study, the primary objective of the PRTX-100-104 Study is to assess the safety and tolerability of intravenous PRTX-100 administered weekly over five weeks in patients with active RA on methotrexate or leflunomide therapy. The secondary objectives include determining the effects of PRTX-100 on measures of disease activity, assessing the immunogenicity and evaluating the PK parameters after repeated doses, and determining possible relationships between the immunogenicity of PRTX-100 and safety, PK and efficacy parameters.
	In August 2013, following a planned interim safety review by our Independent Data Safety Monitoring Committee (SMC) and upon completion of the fourth cohort, we expanded the 3.0 microgram, 6.0 microgram, and 12.0 micrograms/kg dose cohorts of the PRTX-100-104 Study. An additional nine patients were enrolled in the expansion cohort that was completed in October 2013. In total, the first four dose-escalating cohorts of the PRTX-100-104 Study, which included these three expanded cohorts, enrolled 41 patients with doses ranging from 1.5 micrograms/kg up to 12.0 micrograms/kg.
	In November 2013, following completion of the Cohort 4 expansion cohorts, we initiated enrollment of the fifth and final cohort (Cohort 5) in the PRTX 100-104 Study. The Cohort 5 sub-study will enroll up to 20 patients who will receive five weekly doses of PRTX-100 followed by four additional monthly maintenance doses of PRTX-100 in the 3.0 micrograms/kg to 6.0 micrograms/kg range. Patients could receive up to nine doses of PRTX-100 over the six month study visit period. The primary objective of the Cohort 5 sub-study is to assess safety and tolerability of these doses administered on a modified schedule.  Secondary objectives include determining the effects of PRTX-100 on measures of disease activity, assessing the immunogenicity and evaluating the PK parameters after repeated doses, and determining possible relationships between the immunogenicity of PRTX-100 and safety, PK and efficacy parameters.
	Currently, all 20 patients have been enrolled into Cohort 5 at six study sites in the United States. A total of nine study sites were used in the PRTX-100-104 Study.
	We maintain an administrative office in Florham Park, New Jersey and currently outsource all of our product development and regulatory activities, including clinical trial activities, manufacturing and laboratory operations, to third-party contract research organizations, consultants and facilities.
	In April 2009, under prior management, we ceased all operations and terminated all employees in light of insufficient funds to continue our clinical trials and related product development. Our business was dormant until current management took control of our operations in November 2009 following the change in control transaction more fully described below. We are currently actively pursuing the commercial development of PRTX-100 for the treatment of RA.
	On December 8, 2010, we effected a reverse stock split of the outstanding shares of our common stock, with par value of $0.00001 per share (“Common Stock”), on the basis of one new share of Common Stock for each five shares of Common Stock outstanding. All references in this Report to number of shares, price per share and weighted average number of shares outstanding of Common Stock prior to this reverse stock split have been adjusted to reflect the reverse stock split on a retroactive basis, unless otherwise noted.

CHANGE_OF_OWNERSHIP_TRANSACTIO

CHANGE OF OWNERSHIP TRANSACTION	9 Months Ended
	Feb. 28, 2014
Working Capital Information [Abstract]	'
CHANGE OF OWNERSHIP TRANSACTION	'
	NOTE 2. CHANGE OF OWNERSHIP TRANSACTION
	On November 11, 2009 (the “Effective Date”), we consummated a financing transaction (the “Financing”) in which we raised $3,000,000 of working capital pursuant to a Securities Purchase Agreement (the “Purchase Agreement”) with Niobe Ventures, LLC, a Delaware limited liability company (“Niobe”). Pursuant to the Purchase Agreement, we issued to Niobe (i) 8,695,652 restricted shares of our Common Stock at a purchase price of $0.23 per share (or $2 million in the aggregate) and (ii) a senior secured convertible promissory note in the principal amount of $1 million convertible into shares of our Common Stock at an initial conversion price equal to $0.23 per share (the “$1 Million Secured Note”). On February 11, 2011, Niobe converted the $1 Million Secured Note, including $37,500 of accrued interest thereon, into 4,510,870 shares of Common Stock.
	As contemplated by the Purchase Agreement, all of our executive officers and all of the members of our Board of Directors (the “Board”) prior to the closing of the Financing, with the exception of Frank M. Dougherty, resigned effective concurrently with the closing of the Financing.  Mr. Dougherty resigned effective upon the expiration of the 10-day notice period required by Rule 14f-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).  In addition, effective upon the closing of the Financing, our Board appointed Arnold P. Kling as a director and then elected him as our president and elected Kirk M. Warshaw as our chief financial officer and secretary.
	In addition, on the Effective Date, we terminated (i) the Investor Rights Agreement dated September 18, 2003 among us, vSpring SBIC L.P. (“vSpring”) and certain of the investors set forth on Schedule A thereto and the Registration Rights Agreement dated May 25, 2005 among us, vSpring and certain of the investors set forth on Schedule I thereto in accordance with their respective terms and (ii) stock options exercisable for an aggregate of 246,714 shares of Common Stock (approximately 41% of our then outstanding stock options).
	On February 11, 2011, for the purpose of providing us with additional working capital, pursuant to an existing Credit Facility Agreement dated as of December 2, 2009 (the “Facility”) with Niobe, we issued to Niobe a senior secured convertible promissory note in the principal amount of $2 million (the “$2 Million Secured Convertible Note”). The $2 Million Secured Convertible Note provided for conversion into shares of our Common Stock at a conversion price of $0.23 per share, for an aggregate of 8,695,652 shares of our Common Stock (net of accrued interest thereon), bore interest at a rate of 3% per annum and matured on December 31, 2013. The original maturity was December 31, 2012 but in December 2012 Niobe agreed, for no consideration, to extend the maturity date to December 31, 2013.
	The $2 Million Secured Convertible Note was convertible at any time, by the holder, subject only to the requirement that we have sufficient authorized shares of Common Stock after taking into account all outstanding shares of Common Stock and the maximum number of shares issuable under all issued and outstanding convertible securities.  In addition, the $2 Million Secured Convertible Note would automatically be converted if we undertake certain Fundamental Transactions, as defined in the $2 Million Secured Convertible Note, (such as a merger, sale of all of our assets, exchange or tender offer, or reclassification of our stock or compulsory exchange).  The $2 Million Secured Convertible Note also provided for the adjustment of the conversion price in the event of stock dividends and stock splits, and provided for acceleration of maturity, at the holder’s option, upon an event of default, as defined in the $2 Million Secured Convertible Note. On August 27, 2013, Niobe converted the principal and accrued interest under the $2 Million Secured Convertible Note of $155,000 into 9,369,565 shares of Common Stock.
	On February 1, 2012, we raised $1,000,000 of working capital pursuant to a loan from Niobe and issued to Niobe a secured promissory note in the principal amount of $1,000,000, which bore interest at a rate of 3% per annum and had a maturity date of February 1, 2014 (the “February 2012 Secured Note”).
	On June 5, 2012, we raised an additional $1,000,000 of working capital pursuant to an incremental loan from Niobe and issued to Niobe a secured promissory note in the principal amount of $1,000,000, which bore interest at a rate of 3% per annum and had a maturity date of May 31, 2014 (the “June 2012 Secured Note”).
	On October 1, 2012, we raised $800,000 of additional working capital pursuant to an incremental loan from Niobe and issued to Niobe a secured promissory note in the principal amount of $800,000, which bore interest at a rate of 3% per annum and had a maturity date of October 1, 2014 (the “October 2012 Secured Note”).
	On December 3, 2012, we raised $700,000 of additional working capital pursuant to an incremental loan from Niobe and issued to Niobe a secured promissory note in the principal amount of $700,000, which bore interest at a rate of 3% per annum and had a maturity date of October 1, 2014 (the “December 2012 Secured Note”).
	Collectively, the February 2012 Secured Note, the June 2012 Secured Note, the October 2012 Secured Note and the December 2012 Secured Note are hereinafter referred to as the “2012 Secured Notes.”
	On January 18, 2013, we raised $2,500,000 of additional working capital pursuant to an incremental loan from Niobe and issued to Niobe a secured promissory note in the principal amount of $2,500,000, which bore interest at a rate of 3% per annum and had a maturity date of January 15, 2015 (the “January 2013 Secured Note”).
	On May 13, 2013, we raised $2,000,000 of additional working capital pursuant to an incremental loan from Niobe and issued to Niobe a secured promissory note in the principal amount of $2,000,000, which bore interest at a rate of 3% per annum and had a maturity date of May 13, 2015 (the “May 2013 Secured Note”).
	On August 27, 2013, the Company raised $1,000,000 of additional working capital pursuant to an incremental loan from Niobe and issued to Niobe a secured promissory note in the principal amount of $1,000,000, which bore interest at a rate of 3% per annum and had a maturity date of August 27, 2015 (the “August 2013 Secured Note”).
	Collectively, the January 2013 Secured Note, the May 2013 Secured Note, and the August 2013 Secured Note are hereinafter referred to as the “2013 Secured Notes.”
	Collectively, the 2012 Secured Notes and the 2013 Secured Notes represented a total of $9,000,000 in principal amount of loans from Niobe and are hereinafter referred to as the “Secured Notes.”
	On October 11, 2013, we issued a Consolidated, Amended and Restated Promissory Note to Niobe in the principal amount of $9,219,366.67 (the “Consolidated Note”).  The face amount of the Consolidated Note reflects the $9.0 million aggregate principal amount of the Secured Notes plus interest accrued at 3% per annum on each note from its respective date of issuance.  The terms of the Consolidated Note are identical to the Secured Notes except that: (a) the maturity date is September 1, 2015, which is after the latest maturity date of any of the Secured Notes; and (b) it provides for partial mandatory repayment in the event that the Company receives aggregate gross proceeds in excess of $7.5 million from a single or multiple “Liquidity Events” in an amount equal to twenty-five (25%) percent of such gross proceeds.  A “Liquidity Event” means (a) the sale of any of our equity, or equity-linked, securities, and (b) the receipt of proceeds, directly or indirectly related to a development and/or commercialization relationship entered into with an unaffiliated third party. In the Secured Notes, the entire principal amount of each note was due, at Niobe’s election, upon the consummation of an equity financing of $7.5 million or greater.  Consistent with the terms of the Secured Notes and related security agreements entered into, our obligations under the Consolidated Note are secured by a first priority perfected security interest in all of our assets pursuant to a Consolidated, Amended and Restated Security Agreement dated October 11, 2013 with Niobe.
	On January 23, 2014, we consummated a private placement financing to accredited investors of 471,334 shares of Common Stock at $6.00 per share resulting in gross proceeds of $2,828,000. We realized net proceeds, after the costs associated with the private placement, of $2,781,603. No commissions were payable in connection with the financing transaction.  Proceeds of the financing will be used for working capital purposes, principally to fund ongoing clinical trials and studies and related activities.  The investors in the offering were granted piggy-back registration rights in connection with certain registration statements filed by us in the future, subject to certain exceptions, including a registration statement filed in connection with a primary offering by us.
	The securities issued in the aforementioned financings were issued in reliance upon the exemption from the registration requirements of the Securities Act of 1933, as amended (the “Act”) pursuant to Sections 4(a)(2) and 4(a)(5) and Regulation D promulgated thereunder.  The offer, sale and issuance of such securities were made without general solicitation or advertising. The securities were offered and issued only to “accredited investors” as such term is defined in Rule 501 under the Act.

GOING_CONCERN

GOING CONCERN	9 Months Ended
	Feb. 28, 2014
Going Concern Disclosure [Abstract]	'
GOING CONCERN	'
	NOTE 3. GOING CONCERN
	The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate our continuation as a going concern. Our ability to continue as a going concern is dependent upon developing products that are regulatory approved and market accepted. There is no assurance that these plans will be realized in whole or in part. The financial statements do not include any adjustments that might result from the outcome of these uncertainties.
	Since inception, we have incurred an accumulated deficit of $69,788,410 through February 28, 2014. For the years ended May 31, 2013 and 2012, we had net losses of $6,280,234 and $4,444,584, respectively, and for the nine months ended February 28, 2014, we had a net loss of $8,053,357. We used $4,733,349 and $2,351,630 of cash in operating activities for the years ended May 31, 2013 and 2012, respectively, and $3,522,190 during the nine months ended February 28, 2014. As of February 28, 2014, we had cash and cash equivalents of $2,716,459 and net working capital of $2,275,878. We incurred negative cash flow from operating activities since our inception. We have spent, and subject to obtaining additional financing, expect to continue to spend, substantial amounts in connection with executing our business strategy, including continued development efforts relating to PRTX-100.
	We have no significant payments due on long-term obligations since, as discussed above in Note 2, on October 11, 2013, we issued the Consolidated Note to Niobe. However, we will need to raise additional capital in the future to fund the ongoing FDA approval process. If we are unable to (a) raise additional capital, (b) obtain approval of future Investigational New Drug Applications (“IND”) that we may file in the future, or (c) otherwise achieve successes in the FDA approval process, our ability to sustain our operations would be significantly jeopardized.
	The most likely sources of additional financing include the public or private sale of equity or debt securities or loans from our majority stockholder. However, additional capital that we may require may not be available on reasonable terms, or at all.
	In February 2014, we filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) in connection with a prospective underwritten public offering of up to 3,000,000 shares of Common Stock. We do not presently have any commitment or understanding with any underwriter with respect to any offering. No assurance can be given that we will pursue or consummate an offering, or if we do, that we will be able to raise sufficient additional working capital to fund our operations and satisfy our debt obligations as they become due.

BASIS_OF_PRESENTATION_AND_SUMM

BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Feb. 28, 2014
Accounting Policies [Abstract]	'
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
	NOTE 4. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	The interim financial data contained in this Report is unaudited; however in the opinion of management, the interim data includes all adjustments, consisting of normal recurring adjustments, necessary for a fair statement of the results for the interim period. The financial statements included herein have been prepared by us pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to such rules and regulations, although we believe that the disclosures included herein are adequate to make the information presented not misleading.  The results of operations in interim periods are not necessarily indicative of the results that may be expected for the full year.
	Information regarding the our organization and business, accounting policies followed by us and other important information is contained in the notes to the financial statements included in our Annual Report on Form 10-K for the fiscal year ended May 31, 2013. This quarterly report should be read in conjunction with such annual report.
	Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make estimates and assumptions affecting the reported amounts of assets, liabilities, revenues and expense, and the disclosure of contingent assets and liabilities. Estimated amounts could differ materially from actual results.
	Loss Per Common Share
	The Financial Accounting Standards Board (FASB) has issued guidance for “Earnings Per Share” which provides for the calculation of “Basic” and “Diluted” earnings per share. Basic earnings per share includes no dilution and is computed by dividing net loss to common stockholders by the weighted average number of common shares outstanding for the period. All potentially dilutive securities consisting of employee stock options and warrants have been excluded from the computations since they would be antidilutive. However, these dilutive securities could potentially dilute earnings per share in future periods. As of February 28, 2014 we had potentially dilutive securities consisting of 3,817,543 stock options. As of February 28, 2013, we had potentially dilutive securities consisting of 2,715,543 stock options.
	Cash and Cash Equivalents
	For the purposes of reporting cash flows, we consider all cash accounts which are not subject to withdrawal restrictions or penalties, and highly liquid investments with original maturities of 60 days or less to be cash and cash equivalents. The cash and cash equivalent deposits are not insured by The Federal Deposit Insurance Corporation.
	Share Based Compensation
	Effective June 1, 2006, we adopted the FASB accounting guidance for fair value recognition provisions of the “Accounting for Share-Based Payment” using the modified prospective method. This standard requires us to measure the cost of employee services received in exchange for equity share options granted based on the grant-date fair value of the options. The cost is recognized as compensation expense over the vesting period of the options. Under the modified prospective method $4,568,763 and $658,488 compensation cost is included in operating expenses for the nine months ended February 28, 2014 and February 28, 2013, respectively. These amounts included both the compensation cost of stock options granted prior to but not yet vested as of June 1, 2006 and compensation cost for all options granted subsequent to May 31, 2006. In accordance with the modified prospective application transition method, prior period results are not restated.  Incremental compensation cost for a modification of the terms or conditions of an award is measured by comparing the fair value of the modified award with the fair value of the award immediately before the modification. No tax benefit was recorded as of February 28, 2014 in connection with these compensation costs due to the uncertainty regarding ultimate realization of certain net operating loss carryforwards. We have also implemented the SEC interpretations in Staff Accounting Bulletin (“SAB”) for “Share-Based Payments,” in connection with the adoption of FASB accounting guidance.
	The Board of Directors adopted and the stockholders approved the 2003 Stock Option Plan in October 2003 which was subsequently amended in October 2005. The plan was adopted to recognize the contributions made by our employees, officers, consultants, and directors, to provide those individuals with additional incentive to devote themselves to our future success, and to improve our ability to attract, retain and motivate individuals upon whom our growth and financial success depends. Under the plan, stock options for up to 900,000 shares may be granted as approved by the Board of Directors or the Compensation Committee.  No options granted under the plan are exercisable after the expiration of ten years (or less in the discretion of the Board of Directors or the Compensation Committee) from the date of the grant. The plan will continue in effect until terminated or amended by the Board of Directors.
	The accounting guidance requires the use of a valuation model to calculate the fair value of each stock-based award. We use the Black-Scholes model to estimate the fair value of stock options granted based on the following assumptions:
	Expected Term or Life. The expected term or life of stock options granted issued represents the expected weighted average period of time from the date of grant to the estimated date that the stock option would be fully exercised. The weighted average expected option term was determined using a combination of the “simplified method” for plain vanilla options as allowed by the accounting guidance. The “simplified method” calculates the expected term as the average of the vesting term and original contractual term of the options.
	Expected Volatility. Expected volatility is a measure of the amount by which our stock price is expected to fluctuate. Expected volatility is based on the historical daily volatility of the price of our shares of Common Stock. We estimated the expected volatility of the stock options at grant date.
	Risk-Free Interest Rate. The risk-free interest rate is based on the implied yield on U.S. Treasury zero-coupon issues with remaining terms equivalent to the expected term of our stock-based awards.
	As of February 28, 2014, there were 3,817,543 stock options outstanding of which an aggregate of 37,000 were options granted under the plan and 3,780,543 were non-plan option grants.  At February 28, 2014, the aggregate unrecognized compensation cost of unvested options, as determined using a Black-Scholes option valuation model, was approximately $2,865,486 (net of estimated forfeitures) which will be recognized ratably through February 2016.  The remaining amount of options will be valued once they vest upon future events. During the nine months ended February 28, 2014, we granted 800,000 stock options and 40,000 options expired. The 800,000 options issued during the nine months ended February 28, 2014 were issued at market.
	The fair value of the options is estimated on the date of the grant using the Black-Scholes option pricing model with the following assumptions:
						From Inception
		Nine Months Ended		Nine Months Ended		Through
		February 28, 2014		February 28, 2013		February 28, 2014
	Dividends per year		0		0		0
	Volatility percentage		418% - 443%		299%		90%-443%
	Risk free interest rate		2.13%		1.74%		1.74%-5.11%
	Expected life (years)		7.0-10.0		7.0-10.0		10-Mar
	Weighted Average Fair Value	$	8.64	$	1.36	$	2.55

RECENT_ACCOUNTING_PRONOUNCEMEN

RECENT ACCOUNTING PRONOUNCEMENTS	9 Months Ended
	Feb. 28, 2014
Accounting Changes and Error Corrections [Abstract]	'
RECENT ACCOUNTING PRONOUNCEMENTS	'
	NOTE 5. RECENT ACCOUNTING PRONOUNCEMENTS
	Our management does not believe that any recently issued, but not yet effective, accounting standards could have a material effect on the accompanying consolidated financial statements. As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances.

RELATED_PARTIES

RELATED PARTIES	9 Months Ended
	Feb. 28, 2014
Related Party Transactions [Abstract]	'
RELATED PARTIES	'
	NOTE 6. RELATED PARTIES
	Niobe, the majority holder of our Common Stock and the holder of the Consolidated Note (defined in Note 2 above), is controlled by Arnold P. Kling, our president and a director.
	During the fiscal year ended May 31, 2013, we issued option for 350,000 shares of Common Stock to Kirk M. Warshaw, our chief financial officer and a director. This option expires ten years from the date of grant (May 22, 2013), and has an exercise price of $1.05 per share. The options vested 50% upon issuance and the remainder will vest on the one-year anniversary of the date of grant (May 22, 2014). The option was valued at $329,000.
	From March 1, 2010 through December 31, 2013, our principal offices were located at 133 Summit Avenue, Suite 22, Summit, New Jersey which property was owned by Kirk M. Warshaw, LLC (the “LLC”), an affiliated company of Mr. Warshaw. Pursuant to our agreement with the LLC, through December 31, 2013, we paid a monthly fee of $500 to the LLC for the use and occupancy, and administrative services, related to our principal offices.

SENIOR_SECURED_CONVERTIBLE_NOT

SENIOR SECURED CONVERTIBLE NOTES - RELATED PARTY	9 Months Ended
	Feb. 28, 2014
Debt Disclosure [Abstract]	'
SENIOR SECURED CONVERTIBLE NOTES - RELATED PARTY	'
	NOTE 7. SENIOR SECURED CONVERTIBLE NOTES - RELATED PARTY
	On the Effective Date (defined in Note 2, above), we issued the $1 Million Secured Note to Niobe, the majority stockholder of Common Stock which is controlled by Arnold P. Kling, our president and a director.  The $1 Million Secured Note bore interest at a rate of 3% per annum and had a scheduled maturity date of November 13, 2012.  Our obligations under the $1 Million Secured Note were secured by a Security Agreement dated the Effective Date (the “Security Agreement”) which granted Niobe a security interest in substantially all of our personal property and assets, including our intellectual property. On February 11, 2011, Niobe converted the $1 Million Secured Note, including $37,500 of accrued interest thereon, into 4,510,870 shares of Common Stock.
	On December 2, 2009, we entered into the Facility (defined in Note 2, above) with Niobe pursuant to which Niobe agreed to provide up to $2,000,000 of additional capital in the form of secured loans at any time prior to June 30, 2012, subject to the achievement of certain predetermined benchmarks. In connection with the Facility, on December 2, 2009, the Security Agreement securing our obligations under the $1 Million Secured Note was amended and restated to also secure any incremental obligations under the Facility (the “Amended Security Agreement”). Pursuant to the Amended Security Agreement, Niobe has a security interest in substantially all of our personal property and assets, including our intellectual property to collateralize all amounts due to it under the $1 Million Secured Note and the Facility.
	Pursuant to the Facility, on February 11, 2011, we received $2,000,000 of additional working capital from Niobe and issued the $2 Million Secured Note to Niobe. The $2 Million Secured Note bore interest at a rate of 3% per annum and, as amended, was scheduled to mature on December 31, 2013. On August 27, 2013, Niobe converted the $2 Million Secured Convertible Note and $155,000 of accrued interest thereunder into 9,369,565 shares of Common Stock.

SENIOR_SECURED_NOTES_RELATED_P

SENIOR SECURED NOTES - RELATED PARTY	9 Months Ended
	Feb. 28, 2014
Debt Disclosure [Abstract]	'
SENIOR SECURED NOTES - RELATED PARTY	'
	NOTE 8. SENIOR SECURED NOTES - RELATED PARTY
	On February 1, 2012, we raised $1,000,000 of working capital pursuant to a loan from Niobe and issued to Niobe a secured promissory note in the principal amount of $1,000,000, which bore interest at a rate of 3% per annum and had a maturity date of February 1, 2014 (the “February 2012 Secured Note”).
	On June 5, 2012, we raised an additional $1,000,000 of working capital pursuant to an incremental loan from Niobe and issued to Niobe a secured promissory note in the principal amount of $1,000,000, which bore interest at a rate of 3% per annum and had a maturity date of May 31, 2014 (the “June 2012 Secured Note”).
	On October 1, 2012, we raised $800,000 of additional working capital pursuant to an incremental loan from Niobe and issued to Niobe a secured promissory note in the principal amount of $800,000, which bore interest at a rate of 3% per annum and had a maturity date of October 1, 2014 (the “October 2012 Secured Note”).
	On December 3, 2012, we raised $700,000 of additional working capital pursuant to an incremental loan from Niobe and issued to Niobe a secured promissory note in the principal amount of $700,000, which bore interest at a rate of 3% per annum and had a maturity date of October 1, 2014 (the “December 2012 Secured Note”).
	Collectively, the February 2012 Secured Note, the June 2012 Secured Note, the October 2012 Secured Note and the December 2012 Secured Note are hereinafter referred to as the “2012 Secured Notes.”
	On January 18, 2013, we raised $2,500,000 of additional working capital pursuant to an incremental loan from Niobe and issued to Niobe a secured promissory note in the principal amount of $2,500,000, which bore interest at a rate of 3% per annum and had a maturity date of January 15, 2015 (the “January 2013 Secured Note”).
	On May 13, 2013, we raised $2,000,000 of additional working capital pursuant to an incremental loan from Niobe and issued to Niobe a secured promissory note in the principal amount of $2,000,000, which bore interest at a rate of 3% per annum and had a maturity date of May 13, 2015 (the “May 2013 Secured Note”).
	On August 27, 2013, the Company raised $1,000,000 of additional working capital pursuant to an incremental loan from Niobe and issued to Niobe a secured promissory note in the principal amount of $1,000,000, which bore interest at a rate of 3% per annum and had a maturity date of August 27, 2015 (the “August 2013 Secured Note”).
	Collectively, the January 2013 Secured Note, the May 2013 Secured Note, and the August 2013 Secured Note are hereinafter referred to as the “2013 Secured Notes.”
	Collectively, the 2012 Secured Notes and the 2013 Secured Notes represent a total of $9,000,000 in principal amount of loans from Niobe and are hereinafter referred to as the “Secured Notes.”
	On October 11, 2013, we issued a Consolidated, Amended and Restated Promissory Note to Niobe in the principal amount of $9,219,366.67 (the “Consolidated Note”).  The face amount of the Consolidated Note reflects the $9.0 million aggregate principal amount of the Secured Notes plus interest accrued at 3% per annum on each note from its respective date of issuance.  The terms of the Consolidated Note are identical to the Secured Notes except that: (a) the maturity date is September 1, 2015, which is after the latest maturity date of any of the Secured Notes; and (b) it provides for partial mandatory repayment in the event that the Company receives aggregate gross proceeds in excess of $7.5 million from a single or multiple “Liquidity Events” in an amount equal to twenty-five (25%) percent of such gross proceeds.  A “Liquidity Event” means (a) the sale of any of our equity, or equity-linked, securities, and (b) the receipt of proceeds, directly or indirectly related to a development and/or commercialization relationship entered into with an unaffiliated third party. In the Secured Notes, the entire principal amount of each note was due, at Niobe’s election, upon the consummation of an equity financing of $7.5 million or greater.  Consistent with the terms of the Secured Notes and related security agreements entered into, our obligations under the Consolidated Note are secured by a first priority perfected security interest in all of our assets pursuant to a Consolidated, Amended and Restated Security Agreement dated October 11, 2013 with Niobe.
	The securities issued in the aforementioned financings were issued in reliance upon the exemption from the registration requirements of the Act pursuant to Sections 4(a)(2) and 4(a)(5) and Regulation D promulgated thereunder.  The offer, sale and issuance of such securities were made without general solicitation or advertising. The securities were offered and issued only to “accredited investors” as such term is defined in Rule 501 under the Act.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Feb. 28, 2014
Subsequent Events [Abstract]	'
SUBSEQUENT EVENTS	'
	NOTE 9. SUBSEQUENT EVENTS
	We have evaluated subsequent events and have determined that there were no subsequent events to recognize or disclose in these financial statements.

BASIS_OF_PRESENTATION_AND_SUMM1

BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Feb. 28, 2014
Accounting Policies [Abstract]	'
Estimates	'
	Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make estimates and assumptions affecting the reported amounts of assets, liabilities, revenues and expense, and the disclosure of contingent assets and liabilities. Estimated amounts could differ materially from actual results.
Loss per Common Share	'
	Loss Per Common Share
	The Financial Accounting Standards Board (FASB) has issued guidance for “Earnings Per Share” which provides for the calculation of “Basic” and “Diluted” earnings per share. Basic earnings per share includes no dilution and is computed by dividing net loss to common stockholders by the weighted average number of common shares outstanding for the period. All potentially dilutive securities consisting of employee stock options and warrants have been excluded from the computations since they would be antidilutive. However, these dilutive securities could potentially dilute earnings per share in future periods. As of February 28, 2014 we had potentially dilutive securities consisting of 3,817,543 stock options. As of February 28, 2013, we had potentially dilutive securities consisting of 2,715,543 stock options.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	For the purposes of reporting cash flows, we consider all cash accounts which are not subject to withdrawal restrictions or penalties, and highly liquid investments with original maturities of 60 days or less to be cash and cash equivalents. The cash and cash equivalent deposits are not insured by The Federal Deposit Insurance Corporation.
Share Based Compensation	'
	Share Based Compensation
	Effective June 1, 2006, we adopted the FASB accounting guidance for fair value recognition provisions of the “Accounting for Share-Based Payment” using the modified prospective method. This standard requires us to measure the cost of employee services received in exchange for equity share options granted based on the grant-date fair value of the options. The cost is recognized as compensation expense over the vesting period of the options. Under the modified prospective method $4,568,763 and $658,488 compensation cost is included in operating expenses for the nine months ended February 28, 2014 and February 28, 2013, respectively. These amounts included both the compensation cost of stock options granted prior to but not yet vested as of June 1, 2006 and compensation cost for all options granted subsequent to May 31, 2006. In accordance with the modified prospective application transition method, prior period results are not restated.  Incremental compensation cost for a modification of the terms or conditions of an award is measured by comparing the fair value of the modified award with the fair value of the award immediately before the modification. No tax benefit was recorded as of February 28, 2014 in connection with these compensation costs due to the uncertainty regarding ultimate realization of certain net operating loss carryforwards. We have also implemented the SEC interpretations in Staff Accounting Bulletin (“SAB”) for “Share-Based Payments,” in connection with the adoption of FASB accounting guidance.
	The Board of Directors adopted and the stockholders approved the 2003 Stock Option Plan in October 2003 which was subsequently amended in October 2005. The plan was adopted to recognize the contributions made by our employees, officers, consultants, and directors, to provide those individuals with additional incentive to devote themselves to our future success, and to improve our ability to attract, retain and motivate individuals upon whom our growth and financial success depends. Under the plan, stock options for up to 900,000 shares may be granted as approved by the Board of Directors or the Compensation Committee.  No options granted under the plan are exercisable after the expiration of ten years (or less in the discretion of the Board of Directors or the Compensation Committee) from the date of the grant. The plan will continue in effect until terminated or amended by the Board of Directors.
	The accounting guidance requires the use of a valuation model to calculate the fair value of each stock-based award. We use the Black-Scholes model to estimate the fair value of stock options granted based on the following assumptions:
	Expected Term or Life. The expected term or life of stock options granted issued represents the expected weighted average period of time from the date of grant to the estimated date that the stock option would be fully exercised. The weighted average expected option term was determined using a combination of the “simplified method” for plain vanilla options as allowed by the accounting guidance. The “simplified method” calculates the expected term as the average of the vesting term and original contractual term of the options.
	Expected Volatility. Expected volatility is a measure of the amount by which our stock price is expected to fluctuate. Expected volatility is based on the historical daily volatility of the price of our shares of Common Stock. We estimated the expected volatility of the stock options at grant date.
	Risk-Free Interest Rate. The risk-free interest rate is based on the implied yield on U.S. Treasury zero-coupon issues with remaining terms equivalent to the expected term of our stock-based awards.
	As of February 28, 2014, there were 3,817,543 stock options outstanding of which an aggregate of 37,000 were options granted under the plan and 3,780,543 were non-plan option grants.  At February 28, 2014, the aggregate unrecognized compensation cost of unvested options, as determined using a Black-Scholes option valuation model, was approximately $2,865,486 (net of estimated forfeitures) which will be recognized ratably through February 2016.  The remaining amount of options will be valued once they vest upon future events. During the nine months ended February 28, 2014, we granted 800,000 stock options and 40,000 options expired. The 800,000 options issued during the nine months ended February 28, 2014 were issued at market.
	The fair value of the options is estimated on the date of the grant using the Black-Scholes option pricing model with the following assumptions:
						From Inception
		Nine Months Ended		Nine Months Ended		Through
		February 28, 2014		February 28, 2013		February 28, 2014
	Dividends per year		0		0		0
	Volatility percentage		418% - 443%		299%		90%-443%
	Risk free interest rate		2.13%		1.74%		1.74%-5.11%
	Expected life (years)		7.0-10.0		7.0-10.0		10-Mar
	Weighted Average Fair Value	$	8.64	$	1.36	$	2.55

BASIS_OF_PRESENTATION_AND_SUMM2

BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
	Feb. 28, 2014
Accounting Policies [Abstract]	'
Fair Value of Assumptions of Options Estimated On Grant Date	'
	The fair value of the options is estimated on the date of the grant using the Black-Scholes option pricing model with the following assumptions:
						From Inception
		Nine Months Ended		Nine Months Ended		Through
		February 28, 2014		February 28, 2013		February 28, 2014
	Dividends per year		0		0		0
	Volatility percentage		418% - 443%		299%		90%-443%
	Risk free interest rate		2.13%		1.74%		1.74%-5.11%
	Expected life (years)		7.0-10.0		7.0-10.0		10-Mar
	Weighted Average Fair Value	$	8.64	$	1.36	$	2.55

ORGANIZATION_AND_BUSINESS_ACTI1

ORGANIZATION AND BUSINESS ACTIVITIES - Additional Information (Detail) (USD $)	1 Months Ended						9 Months Ended
	Nov. 30, 2013	Oct. 31, 2013	Aug. 31, 2013	Nov. 30, 2012	Jan. 31, 2012	Aug. 31, 2010	Feb. 28, 2014	31-May-13	Dec. 08, 2010
Organization and Nature Of Operations [Line Items]	'	'	'	'	'	'	'	'	'
Reverse stock split, Common stock, par value	'	'	'	'	'	'	$0.00	$0.00	$0.00
Number of patients approved to enroll in four dose escalating cohorts	'	'	'	40	'	40	'	'	'
Number of patients enrolled in four dose escalating cohorts	20	9	41	'	37	'	20	'	'

CHANGE_OF_OWNERSHIP_TRANSACTIO1

CHANGE OF OWNERSHIP TRANSACTION - Additional Information (Detail) (USD $)

1 Months Ended

9 Months Ended

12 Months Ended

1 Months Ended

1 Months Ended

0 Months Ended

25-May-05

Feb. 28, 2014

31-May-00

31-May-00

31-May-11

31-May-10

31-May-02

31-May-01

Jan. 23, 2014

Oct. 11, 2013

Aug. 27, 2013

13-May-13

Jan. 18, 2013

Dec. 03, 2012

Oct. 01, 2012

Jun. 05, 2012

Feb. 01, 2012

Feb. 28, 2014

Nov. 11, 2009

Feb. 11, 2011

Nov. 11, 2009

Feb. 11, 2011

Private Placement

Senior Secured Note

Niobe Ventures LLC

Niobe Ventures LLC

Niobe Ventures LLC

Niobe Ventures LLC

Niobe Ventures LLC

Niobe Ventures LLC

Niobe Ventures LLC

Niobe Ventures LLC

Niobe Ventures LLC

Niobe Ventures LLC

Niobe Ventures LLC

Credit Facility Agreement

Senior Secured Note

Senior Secured Note

Senior Secured Note

Senior Secured Note

Senior Secured Note

Senior Secured Note

Senior Secured Note

Senior Secured Note

Securities Purchase Agreement

Securities Purchase Agreement

Securities Purchase Agreement

Niobe Ventures LLC

Senior Secured Note

Senior Secured Note

Senior Secured Note

Class of Stock [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Additional working capital raised

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$3,000,000

'

'

'

Restricted shares of common stock issued

'

800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8,695,652

'

'

'

Common Stock issued, per share

'

'

$0.15

$0.15

'

$0.23

$6.25

$5

'

'

'

'

'

'

'

'

'

'

$0.23

'

'

'

Restricted shares of common stock issued, value

'

'

'

'

1,037,500

2,000,000

1,102,000

425,000

'

'

'

'

'

'

'

'

'

'

2,000,000

'

'

'

Senior secured convertible promissory note

'

'

'

'

'

'

'

'

'

'

2,000,000

'

'

'

'

'

'

'

'

1,000,000

1,000,000

2,000,000

Accrued interest on senior secured convertible promissory note

'

'

'

'

'

'

'

'

'

'

155,000

'

'

'

'

'

'

'

'

37,500

'

'

Senior secured convertible promissory note, conversion price per share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.23

$0.23

Shares of common stock issuable upon conversion of senior secured convertible promissory note

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,510,870

'

'

Senior secured convertible promissory note, maturity date

'

'

'

'

'

'

'

'

'

1-Sep-15

27-Aug-15

13-May-15

15-Jan-15

1-Oct-14

1-Oct-14

31-May-14

1-Feb-14

'

'

'

'

31-Dec-12

Senior secured convertible promissory note, extended maturity date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

31-Dec-13

Debt instrument, interest rate, effective percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3.00%

Proceeds from secured notes payable

'

'

'

'

'

'

'

'

'

'

1,000,000

2,000,000

2,500,000

700,000

800,000

1,000,000

1,000,000

'

'

'

'

'

Debt instrument, face amount

'

'

'

'

'

'

'

'

'

9,000,000

1,000,000

2,000,000

2,500,000

700,000

800,000

1,000,000

1,000,000

9,000,000

'

'

'

'

Secured note payable, interest rate

'

'

'

'

'

'

'

'

'

3.00%

3.00%

3.00%

3.00%

3.00%

3.00%

3.00%

3.00%

'

'

'

'

'

Debt Conversion, Converted Instrument, Shares Issued

'

'

'

'

'

'

'

'

'

'

9,369,565

'

'

'

'

'

'

'

'

'

'

'

Debt instrument carrying amount

'

'

'

'

'

'

'

'

'

9,219,366.67

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Repayments of secured debt

'

'

'

'

'

'

'

'

'

7,500,000

'

'

'

'

'

'

'

'

'

'

'

'

Terms of consolidated note identical to secured notes

'

'

'

'

'

'

'

'

'

'(a) the maturity date is September 1, 2015, which is after the latest maturity date of any of the Secured Notes; and (b) it provides for partial mandatory repayment in the event that the Company receives aggregate gross proceeds in excess of $7.5 million from a single or multiple “Liquidity Events” in an amount equal to twenty-five (25%) percent of such gross proceeds.

'

'

'

'

'

'

'

'

'

'

'

'

Description of Liquidity Event

'

'

'

'

'

'

'

'

'

'(a) the sale of any of our equity, or equity-linked, securities, and (b) the receipt of proceeds, directly or indirectly related to a development and/or commercialization relationship entered into with an unaffiliated third party.

'

'

'

'

'

'

'

'

'

'

'

'

Consummation of equity financing, amount

'

'

'

'

'

'

'

'

'

7,500,000

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number

246,714

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage For Stock Options Outstanding

41.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock Of Accredited Investors Shares

'

'

'

'

'

'

'

'

471,334

'

'

'

'

'

'

'

'

'

'

'

'

'

Share Price

'

'

'

'

'

'

'

'

$6

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Issuance of Private Placement

'

'

'

'

'

'

'

'

2,828,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds From Realized Cost

'

'

'

'

'

'

'

'

$2,781,603

'

'

'

'

'

'

'

'

'

'

'

'

'

GOING_CONCERN_Additional_Infor

GOING CONCERN - Additional Information (Detail) (USD $)

3 Months Ended

9 Months Ended

12 Months Ended

173 Months Ended

Feb. 28, 2014

Feb. 28, 2013

Feb. 28, 2014

Feb. 28, 2013

31-May-00

31-May-13

31-May-12

31-May-11

31-May-10

31-May-09

31-May-08

31-May-07

31-May-06

31-May-05

31-May-04

31-May-03

31-May-02

31-May-01

Feb. 28, 2014

Sep. 16, 1999

Cash Flow Supplemental Disclosures [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deficit accumulated during the development stage

$69,788,410

'

$69,788,410

'

'

$61,735,053

'

'

'

'

'

'

'

'

'

'

'

'

$69,788,410

'

Net loss

5,049,563

1,615,008

8,053,357

4,400,007

250,689

6,280,234

4,444,584

3,357,882

3,067,842

7,230,206

10,490,758

8,451,942

6,104,402

5,567,729

2,989,364

1,665,090

1,280,465

553,866

69,788,410

'

Cash used in operating activities

'

'

3,522,190

'

'

4,733,349

2,351,630

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash and cash equivalents

2,716,459

1,704,458

2,716,459

1,704,458

'

2,457,046

190,395

'

'

'

'

'

'

'

'

'

'

'

2,716,459

0

Net working capital deficit

$2,275,878

'

$2,275,878

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2,275,878

'

Stock Issued During Period Shares New Issues

'

'

800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Underwritten Public Offering

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash Flow Supplemental Disclosures [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period Shares New Issues

'

'

3,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

BASIS_OF_PRESENTATION_AND_SUMM3

BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Detail) (USD $)	9 Months Ended
	Feb. 28, 2014	Feb. 28, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Aggregate unrecognized compensation cost of unvested options	$2,865,486	'
Share based compensation, number of stock options expired during period	40,000	'
Share-based compensation arrangement by share-based payment award, options, grants in period, gross	800,000	'
Options issued	800,000	'
Plan Option Grants	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share based compensation, number of stock options outstanding	37,000	'
Non Plan Option Grants	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Number of shares reserved for grants of options	3,780,543	'
Stock Incentive Plan 2003	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Number of shares reserved for grants of options	900,000	'
Operating Expense	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Compensation cost included in operating expenses	$4,568,763	$658,488
Stock Option	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Potentially dilutive securities	3,817,543	2,715,543

Fair_Value_of_Assumptions_of_O

Fair Value of Assumptions of Options Estimated on Grant Date (Detail) (USD $)	9 Months Ended		173 Months Ended	9 Months Ended		173 Months Ended	9 Months Ended		173 Months Ended
	Feb. 28, 2014	Feb. 28, 2013	Feb. 28, 2014	Feb. 28, 2014	Feb. 28, 2013	Feb. 28, 2014	Feb. 28, 2014	Feb. 28, 2013	Feb. 28, 2014
				Minimum	Minimum	Minimum	Maximum	Maximum	Maximum
Assumptions used to Determine Fair Value Options [Line Items]	'	'	'	'	'	'	'	'	'
Dividends per year	$0	$0	$0	'	'	'	'	'	'
Volatility percentage	'	299.00%	'	418.00%	'	90.00%	443.00%	'	443.00%
Risk free interest rate	2.13%	1.74%	'	'	'	1.74%	'	'	5.11%
Expected life (years)	'	'	'	'7 years	'7 years	'3 years	'10 years	'10 years	'10 years
Weighted Average Fair Value	$8.64	$1.36	$2.55	'	'	'	'	'	'

RELATED_PARTIES_Additional_Inf

RELATED PARTIES - Additional Information (Detail) (USD $)	9 Months Ended	1 Months Ended	12 Months Ended
	Feb. 28, 2014	Mar. 01, 2010	31-May-13
		Monthly Payment	Mr. Warshaw
Related Party Transaction [Line Items]	'	'	'
Payment for the use and occupancy, and administrative services, related to principal offices	'	$500	'
Share-based compensation arrangement by share-based payment award, options, grants in period, gross	800,000	'	350,000
Share-based compensation arrangement by share-based payment award, award vesting period	'	'	'10 years
Weighted average exercise price of options	'	'	$1.05
Share-based compensation arrangement by share-based payment award, award vesting rights	'	'	'The options vested 50% upon issuance and the remainder will vest on the one-year anniversary of the date of grant (May 22, 2014).
Fair value of options	'	'	$329,000

SENIOR_SECURED_CONVERTIBLE_NOT1

SENIOR SECURED CONVERTIBLE NOTES - RELATED PARTY - Additional Information (Detail) (USD $)	0 Months Ended	1 Months Ended
	Feb. 11, 2011	Aug. 27, 2013	Nov. 11, 2009	Dec. 02, 2009
Debt Instrument [Line Items]	'	'	'	'
Secured note payable, additional borrowing amount	$2,000,000	'	'	'
Convertible debt, current	'	'	'	1,000,000
Niobe Ventures, LLC | Senior Secured Convertible Notes	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'
Secured note payable, additional borrowing amount	'	'	'	2,000,000
Debt instrument, face amount	2,000,000	'	1,000,000	'
Debt instrument, interest rate during Period	3.00%	'	3.00%	'
Secured note payable, maturity date	31-Dec-13	'	13-Nov-12	'
Debt conversion, converted instrument, shares issued	4,510,870	9,369,565	'	'
Convertible debt, current	1,000,000	'	'	'
Accrued interest on senior secured convertible promissory note	37,500	155,000	'	'
Debt Conversion, Converted Instrument, Amount	'	$2,000,000	'	'

SENIOR_SECURED_NOTES_RELATED_P1

SENIOR SECURED NOTES - RELATED PARTY - Additional Information (Detail) (Senior Secured Notes, USD $)	1 Months Ended
	Oct. 11, 2013	Oct. 11, 2013	Aug. 27, 2013	13-May-13	Jan. 18, 2013	Dec. 03, 2012	Oct. 01, 2012	Jun. 05, 2012	Feb. 01, 2012	Aug. 31, 2013
		Minimum	Niobe Ventures, LLC	Niobe Ventures, LLC	Niobe Ventures, LLC	Niobe Ventures, LLC	Niobe Ventures, LLC	Niobe Ventures, LLC	Niobe Ventures, LLC	Niobe Ventures, LLC
Debt Instrument [Line Items]	'	'	'	'	'	'	'	'	'	'
Proceeds from issuance of secured note	'	'	$1,000,000	$2,000,000	$2,500,000	$700,000	$800,000	$1,000,000	$1,000,000	'
Secured note payable	9,000,000	'	1,000,000	2,000,000	2,500,000	700,000	800,000	1,000,000	1,000,000	9,000,000
Secured note payable, interest rate	3.00%	'	3.00%	3.00%	3.00%	3.00%	3.00%	3.00%	3.00%	'
Secured note payable, maturity date	'	'	27-Aug-15	13-May-15	15-Jan-15	1-Oct-14	1-Oct-14	31-May-14	1-Feb-14	'
Debt instrument carrying amount	9,219,366.67	'	'	'	'	'	'	'	'	'
Proceeds from Repayments of secured debt	7,500,000	'	'	'	'	'	'	'	'	'
Terms of consolidated note identical to secured notes	'(a) the maturity date is September 1, 2015, which is after the latest maturity date of any of the Secured Notes; and (b) it provides for partial mandatory repayment in the event that the Company receives aggregate gross proceeds in excess of $7.5 million from a single or multiple Liquidity Events in an amount equal to twenty-five (25%) percent of such gross proceeds.	'	'	'	'	'	'	'	'	'
Description of liquidity event	'(a) the sale of any of our equity, or equity-linked, securities, and (b) the receipt of proceeds, directly or indirectly related to a development and/or commercialization relationship entered into with an unaffiliated third party.	'	'	'	'	'	'	'	'	'
Consummation of equity financing, amount	'	$7,500,000	'	'	'	'	'	'	'	'